Yet analysts are ramping up their growth forecast for the fiscal year 2021. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. View Atara Biotherapeutics, Inc. ATRA investment & stock information. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … In addition, he makes $302,492 as Independent Director at Atara Biotherapeutics Inc. Dennis Seidenberg was born in in July 18, 1981. The stock traded as high as $20.31 and last traded at $20.25. Atara Biotherapeutics last posted its quarterly earnings results on February 28th, 2021. Analyst recommendations provided by FactSet shows that the consensus forecast for Atara Biotherapeutics Inc. (ATRA) is a “Overweight”. Atara Biotherapeutics Inc. (ATRA) shares have gone down -45.63% during the last six months, with a year-to-date growth rate more than the industry average at 14.94% against 9.00. Why Atara Biotherapeutics Stock Is Bolting Higher Today. 10 months ago - Zacks Investment Research Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Since then, ATRA shares have increased by 44.7% and is now trading at $14.41. BIND Therapeutics (NASDAQ: BIND ) shares ended the day 32.77% lower. ATRA's earnings performance is very weak as a result of poor EPS growth over the past 3-5 years and inconsistent earnings over the past 5 years. … Atara Biotherapeutics stock Stock Monthly Prediction for January, February, March, April, May, July, July, August, September, October, November and December 2024. A high-level overview of Atara Biotherapeutics, Inc. (ATRA) stock. Approximately 656,364 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 589,642 shares. 09:32 AM ET. today = new Date(today.getTime() - loop_time * loop_range); CelebsMoney has recently updated Dennis Seidenberg’s net worth. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Atara Biotherapeutics stock. View analyst ratings for Atara Biotherapeutics or view top-rated stocks. What stocks does MarketBeat like better than Atara Biotherapeutics? The average price target is $44.75 with a high forecast of $78.00 and a low forecast of $29.00. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of restricted stock units to acquire 40,800 shares of common stock to ten newly hired … Promoted When trading Atara Biotherapeutics or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. 10 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold … 02-16 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. Add to Portfolio. Research analysts forecast that Atara Biotherapeutics will post -3.89 earnings per share for the current fiscal year. Add to Watchlist. ATRA stock forecast Our latest prediction for Atara Biotherapeutics Inc's stock price was made on the Aug. 18, 2020 when the stock price was at 11.92$. Our corporate headquarters is located in South San Francisco and is supported by our R&D and manufacturing hub which features our new 90,000 sq. ft., state-of-the-art Atara T-Cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. As a group, equities analysts forecast that Atara Biotherapeutics, Inc. will post -3.89 earnings per share for the current fiscal year. Atara Biotherapeutics Inc. (ATRA) estimates and forecasts ATRA Dividend History & Description — Atara Biotherapeutics Inc. Atara Biotherapeutics is an off-the-shelf, allogeneic T-cell immunotherapy company that is developing treatments for patients with cancer, autoimmune and viral diseases. But when you pick a company that is really flourishing, you can make more than 100%. If you are looking for stocks with good return, Atara Biotherapeutics Inc stock can be a bad, high-risk … Of this total $364,494 was received as a salary, $0 was received as a bonus, $909,080 was received in stock options, $1,034,714 was awarded as stock and $20,546 came from other types of compensation. Atara Biotherapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Atara Biotherapeutics stock was originally listed at a price of $10.65 in Oct 16, 2014. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) price on Wednesday, Apr 21, rose 2.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.64. 09:55 AM ET. ATARA BIOTHERAPEUTICS, INC. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: ATRA | Nasdaq Atara Biotherapeutics Inc (ATRA:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Atara Biotherapeutics's share price could stay at $30.33 by May 13, 2022. The stock options have a ten-year term and an exercise price of $13.24 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 10, 2021. Estimated Average Forecasted Atara Biotherapeutics Price: 14.57 Positive intraday dynamics of the instrument is expected with 2.958% volatility is expected. Earnings and Valuation of Atara Biotherapeutics (NASDAQ:ATRA. Past 12 Months 12 Months Forecast $8 $25.8 $43.5 $61.3 $79 Sep This information is according to proxy statements … $14.35. The stock closed 36.75% lower. Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the "Company"), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced President and Chief Executive Officer Pascal Touchon will present Atara’s 2020 … 8 Wall Street analysts have set twelve-month price targets for Atara Biotherapeutics in the last year. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. ATARA BIOTHERAPEUTICS, INC. : Trading strategies, financial analysis, commentaries and investment guidance for ATARA BIOTHERAPEUTICS, INC. Stock | Nasdaq: ATRA | Nasdaq Data is currently not available. Atara Biotherapeutics Inc. ... Supreme forecast to contribute $600 million to VF Corp. revenue this year. Only 4.30% of the stock of Atara Biotherapeutics is held by insiders. In order for the stock price to hit the forecast high, the stock would need to surge +299.59% from its current level, while the stock would need to crash -53.89% from its current level to reach the projected low. Get the hottest stocks to trade every day before the market opens 100% free. A rank of 48 means that 52% of stocks appear more favorable to our system. The stock also has attractive financial metrics. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ATARA BIOTHERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ATARA BIOTHERAPEUTICS, INC. Stock | ATRA | US0465131078 Get the latest Atara Biotherapeutics, Inc. ATRA detailed stock quotes, stock … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Clinical Trial Manager at Atara Biotherapeutics, Inc. University of California, Santa Barbara. Click here now. Atara Biotherapeutics Inc Stock Price Forecast, "ATRA" Predictons for2024 Distance from 52-week low is 83.09% and -51.63% from its 52-week high. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.22. Atara Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 046513107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) Specifically, they have bought $0.00 in company stock and sold $408,752.00 in company stock. Barron's also provides information on historical stock ratings, … How has Atara Biotherapeutics's share price performed over time and what events caused price changes? The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs MarketWatch. Only 4.30% of the stock of Atara Biotherapeutics is held by insiders. Earnings and Valuation of Atara Biotherapeutics (NASDAQ:ATRA. The reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.24. Atara Biotherapeutics, Inc. Common Stock (ATRA) Nasdaq Listed. In other news, insider Joe Newell sold 7,000 shares of the business’s stock in a transaction on Wednesday, December 16th. Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Pessimistic forecast: 14.34 Optimistic: 14.78 Atara Biotherapeutics stock forecast for 24.05.2021. Atara Biotherapeutics (ATRA) stock price prediction is 12.918885 USD. During that period the price should oscillate between -10.17% and +10.84%. Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy? It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Get the latest Atara Biotherapeutics Inc earnings report, revenues as well as upcoming ATRA earnings dates, historical financial reports, news, analysis & more. Chart fundamental metrics like Market Cap, Fair Value, EV/EBITDA, P/E Ratio, Forecasts, Stock Price, Debt / Total Capital and more. SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 611 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080. Find the latest Atara Biotherapeutics, Inc. ATRA analyst stock forecast, price target, … At that level they are trading at 0.118% discount to the analyst consensus target price of 0.00. To hit the forecast high, the stock’s price needs a +460.75% upsurge from its current level, while the stock would need to tank -28.11% for it to hit the projected low. Several analysts have recently […] Atara Biotherapeutics Inc. provides health care services. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the presentation of data from the first part of the ongoing Phase 1 study of ATA188 for the treatment of … Atara Biotherapeutics is followed by the analysts listed above. George Budwell | Dec 29, 2017. Nasdaq 100. A number of … Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($3.89) to ($3.69) per share. Atara Biotherapeutics, Inc. The most you can lose on any stock (assuming you don’t use leverage) is 100% of your money. In the short term (2weeks), ATRA's stock price should underperform the market by -2.08%. The business had revenue of $2.38 billion for the quarter, compared to … On April 11, 2018, Atara Biotherapeutics stock broke out of the symmetrical triangle, and a powerful move toward higher prices followed. Only 4.30% of the stock of Atara Biotherapeutics is held by insiders. View Arthur Wang, M.S, CPIM’S profile on LinkedIn, the world's largest professional community. 5) Atara Biotherapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of … Atara Biotherapeutics To Present 12-Month Data From All Four Cohorts In The Phase 1a Study Of ATA188 In Progressive Multiple Sclerosis At MSVirtual2020 By Business Wire Sep 1, 2020 7:00 AM EDT … You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Atara Biotherapeutics Inc Stock Forecast Over the next 52 weeks, Atara Biotherapeutics Inc has on average historically risen by 8 % based on the past 6 years of stock performance. Arthur has 5 jobs listed on their profile. Specifically, they have bought $0.00 in company stock and sold $408,752.00 in company stock. ATRA / Atara Biotherapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment. To wit, the Atara Biotherapeutics, Inc. (NASDAQ:ATRA) share price has flown 122% in the last three years.Most would be happy with that. Atara Biotherapeutics, Inc. (ATRA) projections and forecasts The average Atara Biotherapeutics stock price prediction forecasts a potential downside of N/A from the current ATRA share price of $13.83. As Former SVP, Corporate Strategy and General Counsel at ATARA BIOTHERAPEUTICS INC, Mina Kim made $2,328,834 in total compensation. The stock had previously closed at $19.05. Specifically, they have bought $0.00 in company stock and sold $301,138.00 in company stock. View which stocks have been most impacted by COVID-19. Canaccord Genuity has the highest price target set, predicting ATRA will reach $78.00 in the next twelve months. The stock options have a ten-year term and an exercise price of $13.97 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on June 1, 2021. Atara Biotherapeutics Stock Forecast NASDAQ:ATRA Price Target and Analyst Ratings. The chart below shows the historical price of Roku stock and a prediction chart for the next year. Atara Biotherapeutics shares were among the biggest losers on the NASDAQ. Headlines about ATRA stock have trended very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will present data in the form of six poster presentations at the … On average, Wall Street analysts predict that . ATARA BIOTHERAPEUTICS INC is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. With Atara Biotherapeutics stock trading at $13.91 per share, the total value of Atara Biotherapeutics stock (market capitalization) is $1.16B. The Atara Biotherapeutics stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Get the hottest stocks to trade every day before the market opens 100% free. Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The Chaikin Power Gauge Rating® for ATRA is Bearish due to very weak earnings performance, very weak price/volume activity and negative expert activity. Atara Biotherapeutics (ATRA, $11.10) designs off-the-shelf, allogeneic T-cell immunotherapy companies, with a primary focus on treating serious diseases. Investors might want to bet on Atara Biotherapeutics (ATRA), as it has been recently upgraded to a Zacks Rank #2 (Buy). View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). Atara Biotherapeutics Inc. (ATRA): The stock medium term indicators say Sell today. Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. Company Releases for Atara Biotherapeutics Inc. Tuesday, Jun 01, 2021. The average price target represents a 210.76% from the last price of $14.40. Insiders buying/selling: Atara Biotherapeutics (NASDAQ:ATRA) In the past three months, Atara Biotherapeutics insiders have sold more of their company’s stock than they have bought. Their average twelve-month price target is $36.63, suggesting a possible upside of 165.4%. ATRA updated stock price target summary. An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($3.89) to ($3.69) per share. For convenience, prices are divided by color. Message board - Online Community of active, educated investors researching and discussing Atara Biotherapeutics, Inc. Stocks. Atara Biotherapeutics has generated ($5.67) earnings per … Atara Biotherapeutics stock forecast for 23.05.2021. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Company offers research and development treatment solutions for cancer, kidney disease, and other illnesses. Shares in Atara Biotherapeutics Inc are currently priced at $15.04. What this means: InvestorsObserver gives ATARA BIOTHERAPEUTICS INC (ATRA) an overall rank of 48, which is below average. Please note that any opinions, estimates or forecasts regarding Atara Biotherapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Atara Biotherapeutics or its management. ... by Product Class, by Type of Therapy, by Indication - Global Forecast to 2025 - Cumulative Impact of COVID-19 GlobeNewswire. Analyst Coverage. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) concluded the trading at $13.94 on Thursday, Apr 15,, with a rise of 0.65% from its closing price on previous day. Do the numbers hold clues to what lies ahead for the stock? View charts for Atara Biotherapeutics, Inc. (NASDAQGS:ATRA). +0.31 (+2.21%) DATA AS OF May 20, 2021. Taking a look at stock … Detailed values for the Roku stock price can be found in the table below. View profile View profile badges Get a job like RUTH’S. The stock options have a ten-year term and an exercise price of $17.10 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on March 1, 2021. The Atara Biotherapeutics Inc. stock is trending slightly upwards today, with an increase of €0.055 (0.490%) compared to yesterday's price. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Based on 5 Wall Street analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. This might drive the stock higher in the near term. Find the latest Atara Biotherapeutics, Inc. (ATRA) stock quote, history, news and other vital information to help you with your stock trading and investing. Wednesday, May 26, 2021. Atara Biotherapeutics. Analysts covering Atara Biotherapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.634 for the next financial year. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics Inc (NASDAQ:ATRA)’s stock price was up 6.3% on Thursday . Click here now. According to analyst projections, ATRA’s forecast low is $10 with $78 as the target high. Atara Biotherapeutics Inc. (ATRA) Analyst Forecasts. Atara Biotherapeutics, Inc. (ATRA) stock forecast and price target. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. More. We predict the dynamics of the stock market value using resonant artificial intelligence systems. Casey’s General Stores last announced its quarterly earnings results on June 7th, 2021. A look at the stock Do the numbers hold clues to what lies ahead for the stock? Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. By Noah Smith June 10, 2021 How have the shares performed? Sometimes, finding the right stock … Data as of 2021-05-22 12:46:57 -0400. ATRA : 14.45 (+4.48%) Atara Biotherapeutics: Q1 Earnings Snapshot AP - … Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). With 2 Buy predictions and 1 Sell predictions the community is currently undecided on Atara Biotherapeutics Inc.. ATRA Stock Predictions, Articles, and Atara Biotherap News From the Web Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new rolePRINCETON, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- … Latest Share Price and Events Stable Share Price : ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. Atara Biotherapeutics Inc has risen higher in 2 of those 6 years over the subsequent 52 week period, corresponding to a historical accuracy of 33.33 %
Corsair Stock Fair Value, Cyclades Board Game Msrp, Essentia Health Medical Records, Ossification Of Flat Bones, Small Intestinal Bacterial Overgrowth Treatment, Tony's Puerto Vallarta, Bangladesh Football Ranking 2021, Circuit Font Generator, Seattle Thunderbirds Wiki,